美国四州潜伏性结核干预的模型成本效果分析
该研究利用结核传播模型,评估在加州、佛州、纽约州和德州对非美国出生者、糖尿病患者、HIV感染者、无家可归者及被监禁者快速扩大LTBI的TTT策略(3HP方案)的成本效果。结果显示TTT的成本效果因州和人群而异,在HIV感染者中最具成本效果,在糖尿病患者中最差。
要点
- 非美国出生者中避免的结核病例数最多,TTT成本效果中等。
核心结论
- TTT for LTBI的成本效果因州和人群而异,但在HIV感染者中始终最高,在糖尿病患者中最低。
研究设计与样本
- 使用结核传播模型,评估在加州、佛州、纽约州和德州对五类高危人群快速扩大TTT(IGRA检测+3HP自服药方案)的成本效果。
主要发现
- 非美国出生者中避免的结核病例数最多,TTT成本效果中等。
- 被监禁或无家可归者中TTT成本效果中等。
临床怎么用
- 在HIV感染者中优先扩大LTBI的TTT策略,可获较好成本效果。
- 对糖尿病患者开展TTT需谨慎评估成本效果。
- 各州应根据人群特点制定差异化LTBI干预策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Targeted testing and treatment (TTT) for latent tuberculosis (TB) infection (LTBI) is a recommended strategy to accelerate TB reductions and further TB elimination in the United States. Evidence on cost-effectiveness of TTT for key populations can help advance this goal. METHODS: We used a model of TB transmission to estimate the numbers of individuals who could be tested by interferon-γ release assay and treated for LTBI with 3 months of self-administered rifapentine and isoniazid (3HP) under various TTT scenarios. Specifically, we considered rapidly scaling up TTT among people who are non-US-born, diabetic, living with human immunodeficiency virus (HIV), homeless or incarcerated in California, Florida, New York, and Texas-states where more than half of US TB cases occur. We projected costs (from the healthcare system perspective, in 2018 dollars), 30-year reductions in TB incidence, and incremental cost-effectiveness (cost per quality-adjusted life-year [QALY] gained) for TTT in each modeled population. RESULTS: The projected cost-effectiveness of TTT differed substantially by state and population, while the health impact (number of TB cases averted) was consistently greatest among non-US-born individuals. TTT was most cost-effective among persons with HIV (from $2828/QALY gained in Florida to $11 265/QALY gained in New York) and least cost-effective among people with diabetes (from $223 041/QALY gained in California to $817 753/QALY in New York). CONCLUSIONS: The modeled cost-effectiveness of TTT for LTBI varies across states but was consistently greatest among people with HIV; moderate among people who are non-US-born, incarcerated, or homeless; and least cost-effective among people with diabetes.
引用
- Jo Y, Shrestha S, Gomes I, et al. Model-based Cost-effectiveness of State-level Latent Tuberculosis Interventions in California, Florida, New York, and Texas. Clin Infect Dis. 2021. PMID: 32584968. doi:10.1093/cid/ciaa857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。